LEGG, L.A.,
TILNEY, R.,
HSIEH, C.F.,
WU, S.,
LUNDSTRÖM, E.,
RUDBERG, A.S.,
KUTLUBAEV, M.A.,
DENNIS, M.,
MEAD, G.E.,
SOLEIMANI, B.,
BARUGH, A.,
HACKETT, M.L.,
HANKEY, G.J (2019) Trials Register (last searched 16 July 2018), the Cochrane
Controlled Trials Register (CENTRAL, Issue 7
Chu, Shuk Han,
Zhao, Xu,
Komber, Ahmad,
Cheyne, Joshua,
Wu, Simiao,
Cowey, Eileen,
Kutlubaev, Mansur,
Mead, Gillian (2023) reviews of
randomized controlled trials found insufficient evidence to guide practice, but most excluded
MEAD, G.E.,
LEGG, L.,
TILNEY, R.,
HSIEH, C.F.,
WU, S.,
LUNDSTRÖM, E.,
RUDBERG, A.S.,
KUTLUBAEV, M.,
DENNIS, M.S.,
SOLEIMANI, B.,
BARUGH, A.,
HACKETT, M.L.,
HANKEY, G.J. (2020) ). There was no difference in the proportion independent (3
trials, n = 3249, 36.6% fluoxetine vs. 36.7%
control; RR 1.00, 95
-quality large-scale, multicenter
randomized clinical
trials (RCTs) are designed and implemented to promote